Treatment with an investigational antibody targeting granulocyte–macrophage colony-stimulating factor (GM-CSF) improved the signs and symptoms of rheumatoid arthritis (RA) in a dose-finding phase II randomized controlled trial. Patients with RA and an inadequate response to methotrexate (n = 92) or anti-TNF therapy (n = 16) received subcutaneous namilumab (20 mg, 80 mg or 150 mg) or placebo at baseline and at weeks 2, 6 and 10. At week 12, disease activity was significantly reduced from baseline in patients treated with all doses of namilumab versus placebo (P = 0.005), with a dose–response effect apparent from week 2.
References
Original article
Taylor, P. C. et al. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Res. Ther. 21, 101 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Namilumab improves RA symptoms. Nat Rev Rheumatol 15, 318 (2019). https://doi.org/10.1038/s41584-019-0231-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0231-9